Literature DB >> 22541630

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.

Jason Grebely1, Maria Prins, Margaret Hellard, Andrea L Cox, William O Osburn, Georg Lauer, Kimberly Page, Andrew R Lloyd, Gregory J Dore.   

Abstract

Hepatitis C virus (HCV) was discovered more than two decades ago, but progress towards a vaccine has been slow. HCV infection will spontaneously clear in about 25% of people. Studies of spontaneous HCV clearance in chimpanzees and human beings have identified host and viral factors that could be important in the control of HCV infection and the design of HCV vaccines. Although data from studies of chimpanzees suggest that protection against reinfection is possible after spontaneous clearance, HCV is a human disease. Results from studies of reinfection risk after spontaneous clearance in injecting drug users are conflicting, but some people seem to have protection against HCV persistence. To guide future vaccine development, we assess data from studies of HCV reinfection after spontaneous clearance, discuss flaws in the methods of previous human studies, and suggest essential components for future investigations of control of HCV infection.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541630      PMCID: PMC3608418          DOI: 10.1016/S1473-3099(12)70010-5

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  79 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.

Authors:  A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

3.  The natural history of hepatitis C virus infection: host, viral, and environmental factors.

Authors:  D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

4.  Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy.

Authors:  S C Ray; Y M Wang; O Laeyendecker; J R Ticehurst; S A Villano; D L Thomas
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 5.  Acute hepatitis C.

Authors:  J R Orland; T L Wright; S Cooper
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

6.  Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population.

Authors:  Barbara A Piasecki; James D Lewis; K Rajender Reddy; Scarlett L Bellamy; Steven B Porter; Robert M Weinrieb; Donald D Stieritz; Kyong-Mi Chang
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

7.  Immunity in hepatitis C infection.

Authors:  A M Prince; B Brotman; T Huima; D Pascual; M Jaffery; G Inchauspé
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

8.  Lack of protective immunity against reinfection with hepatitis C virus.

Authors:  P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

9.  Neutralizing antibody response during acute and chronic hepatitis C virus infection.

Authors:  C Logvinoff; M E Major; D Oldach; S Heyward; A Talal; P Balfe; S M Feinstone; H Alter; C M Rice; J A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

10.  Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children.

Authors:  M E Lai; A P Mazzoleni; F Argiolu; S De Virgilis; A Balestrieri; R H Purcell; A Cao; P Farci
Journal:  Lancet       Date:  1994-02-12       Impact factor: 79.321

View more
  83 in total

Review 1.  Treatment Options in Hepatitis C.

Authors:  Stefan Zeuzem
Journal:  Dtsch Arztebl Int       Date:  2017-01-09       Impact factor: 5.594

2.  The Hotel Study-Clinical and Health Service Effectiveness in a Cohort of Homeless or Marginally Housed Persons.

Authors:  William G Honer; Alejandro Cervantes-Larios; Andrea A Jones; Fidel Vila-Rodriguez; Julio S Montaner; Howard Tran; Jimmy Nham; William J Panenka; Donna J Lang; Allen E Thornton; Talia Vertinsky; Alasdair M Barr; Ric M Procyshyn; Geoffrey N Smith; Tari Buchanan; Mel Krajden; Michael Krausz; G William MacEwan; Kristina M Gicas; Olga Leonova; Verena Langheimer; Alexander Rauscher; Krista Schultz
Journal:  Can J Psychiatry       Date:  2017-02-15       Impact factor: 4.356

3.  Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.

Authors:  Elizabeth R Stevens; Kimberly A Nucifora; Holly Hagan; Ashly E Jordan; Jennifer Uyei; Bilal Khan; Kirk Dombrowski; Don des Jarlais; R Scott Braithwaite
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

4.  Targeted estimation of binary variable importance measures with interval-censored outcomes.

Authors:  Stephanie Sapp; Mark J van der Laan; Kimberly Page
Journal:  Int J Biostat       Date:  2014       Impact factor: 0.968

Review 5.  CD4+ T Cell Differentiation in Chronic Viral Infections: The Tfh Perspective.

Authors:  Laura A Vella; Ramin S Herati; E John Wherry
Journal:  Trends Mol Med       Date:  2017-11-12       Impact factor: 11.951

Review 6.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

Review 7.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

Review 8.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

9.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

10.  The Second Canadian Symposium on hepatitis C virus: a call to action.

Authors:  Jason Grebely; Marc Bilodeau; Jordan J Feld; Julie Bruneau; Benedikt Fischer; Jennifer F Raven; Eve Roberts; Norma Choucha; Rob P Myers; Selena M Sagan; Joyce A Wilson; Frank Bialystok; D Lorne Tyrrell; Michael Houghton; Mel Krajden
Journal:  Can J Gastroenterol       Date:  2013-11       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.